Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis : Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial. / Starzer, Marie Stefanie Kejser; Hansen, Helene Gjervig; Hjorthøj, Carsten; Speyer, Helene; Albert, Nikolai; Nordentoft, Merete.

I: Schizophrenia Bulletin, Bind 49, Nr. 5, 2023, s. 1256–1268.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Starzer, MSK, Hansen, HG, Hjorthøj, C, Speyer, H, Albert, N & Nordentoft, M 2023, 'Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial', Schizophrenia Bulletin, bind 49, nr. 5, s. 1256–1268. https://doi.org/10.1093/schbul/sbad111

APA

Starzer, M. S. K., Hansen, H. G., Hjorthøj, C., Speyer, H., Albert, N., & Nordentoft, M. (2023). Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial. Schizophrenia Bulletin, 49(5), 1256–1268. https://doi.org/10.1093/schbul/sbad111

Vancouver

Starzer MSK, Hansen HG, Hjorthøj C, Speyer H, Albert N, Nordentoft M. Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial. Schizophrenia Bulletin. 2023;49(5):1256–1268. https://doi.org/10.1093/schbul/sbad111

Author

Starzer, Marie Stefanie Kejser ; Hansen, Helene Gjervig ; Hjorthøj, Carsten ; Speyer, Helene ; Albert, Nikolai ; Nordentoft, Merete. / Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis : Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial. I: Schizophrenia Bulletin. 2023 ; Bind 49, Nr. 5. s. 1256–1268.

Bibtex

@article{9207e8afcc674490b5a0a4aec75cecaf,
title = "Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial",
abstract = "BACKGROUND AND HYPOTHESIS: The life expectancy of patients diagnosed with schizophrenia is 10-12 years lower than in the general population and the mortality gap seems to be worsening. Many of these deaths might be avoidable. We aimed to determine mortality rates and causes of death after a first-episode psychosis, and to examine if clinical characteristics at baseline or during illness could predict mortality.STUDY DESIGN: The OPUS study was a randomized controlled trial of 578 patients first diagnosed with schizophrenia spectrum disorders. Patients were clinically assessed after 2, 5, 10, and 20 years. Information about time and cause of death was obtained from the Danish Cause of Death Register. Hazard ratios were used to assess predictors of death.STUDY RESULTS: In total, 82 (14.4%) participants died during 20 years of follow-up. The most common cause of death was suicide (27%). At baseline employment (HR 0.47 P = .049), psychotic disorder other than schizophrenia (HR 0.36, P = .017), and longer duration of untreated psychosis (HR 0.57 P = .042) predicted lower mortality while substance use predicted higher mortality (HR 2.56, P < .001). During follow-up, symptom remission without antipsychotic medication and recovery predicted lower mortality (HR 0.08 P = .013 and HR 0.21, P = .028) while substance use (HR 3.64 P < .001), and all chronic illnesses predicted increased risk.CONCLUSIONS: There is an increased risk of early mortality in schizophrenia compared to the background population, and there is an urgent need for new efforts to improve the disparities in health that lead to this increased mortality.",
author = "Starzer, {Marie Stefanie Kejser} and Hansen, {Helene Gjervig} and Carsten Hjorth{\o}j and Helene Speyer and Nikolai Albert and Merete Nordentoft",
note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2023",
doi = "10.1093/schbul/sbad111",
language = "English",
volume = "49",
pages = "1256–1268",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis

T2 - Evidence From the 20-Year Follow-up of the OPUS Randomized Controlled Trial

AU - Starzer, Marie Stefanie Kejser

AU - Hansen, Helene Gjervig

AU - Hjorthøj, Carsten

AU - Speyer, Helene

AU - Albert, Nikolai

AU - Nordentoft, Merete

N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2023

Y1 - 2023

N2 - BACKGROUND AND HYPOTHESIS: The life expectancy of patients diagnosed with schizophrenia is 10-12 years lower than in the general population and the mortality gap seems to be worsening. Many of these deaths might be avoidable. We aimed to determine mortality rates and causes of death after a first-episode psychosis, and to examine if clinical characteristics at baseline or during illness could predict mortality.STUDY DESIGN: The OPUS study was a randomized controlled trial of 578 patients first diagnosed with schizophrenia spectrum disorders. Patients were clinically assessed after 2, 5, 10, and 20 years. Information about time and cause of death was obtained from the Danish Cause of Death Register. Hazard ratios were used to assess predictors of death.STUDY RESULTS: In total, 82 (14.4%) participants died during 20 years of follow-up. The most common cause of death was suicide (27%). At baseline employment (HR 0.47 P = .049), psychotic disorder other than schizophrenia (HR 0.36, P = .017), and longer duration of untreated psychosis (HR 0.57 P = .042) predicted lower mortality while substance use predicted higher mortality (HR 2.56, P < .001). During follow-up, symptom remission without antipsychotic medication and recovery predicted lower mortality (HR 0.08 P = .013 and HR 0.21, P = .028) while substance use (HR 3.64 P < .001), and all chronic illnesses predicted increased risk.CONCLUSIONS: There is an increased risk of early mortality in schizophrenia compared to the background population, and there is an urgent need for new efforts to improve the disparities in health that lead to this increased mortality.

AB - BACKGROUND AND HYPOTHESIS: The life expectancy of patients diagnosed with schizophrenia is 10-12 years lower than in the general population and the mortality gap seems to be worsening. Many of these deaths might be avoidable. We aimed to determine mortality rates and causes of death after a first-episode psychosis, and to examine if clinical characteristics at baseline or during illness could predict mortality.STUDY DESIGN: The OPUS study was a randomized controlled trial of 578 patients first diagnosed with schizophrenia spectrum disorders. Patients were clinically assessed after 2, 5, 10, and 20 years. Information about time and cause of death was obtained from the Danish Cause of Death Register. Hazard ratios were used to assess predictors of death.STUDY RESULTS: In total, 82 (14.4%) participants died during 20 years of follow-up. The most common cause of death was suicide (27%). At baseline employment (HR 0.47 P = .049), psychotic disorder other than schizophrenia (HR 0.36, P = .017), and longer duration of untreated psychosis (HR 0.57 P = .042) predicted lower mortality while substance use predicted higher mortality (HR 2.56, P < .001). During follow-up, symptom remission without antipsychotic medication and recovery predicted lower mortality (HR 0.08 P = .013 and HR 0.21, P = .028) while substance use (HR 3.64 P < .001), and all chronic illnesses predicted increased risk.CONCLUSIONS: There is an increased risk of early mortality in schizophrenia compared to the background population, and there is an urgent need for new efforts to improve the disparities in health that lead to this increased mortality.

U2 - 10.1093/schbul/sbad111

DO - 10.1093/schbul/sbad111

M3 - Journal article

C2 - 37527479

VL - 49

SP - 1256

EP - 1268

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 5

ER -

ID: 362543569